The goal of the program is to produce outstanding biomedical scientists who investigate the mechanisms, manifestations, prevention, and cures of lung disease. The program combines intensive training in a single area of investigation within a multidisciplinary academic environment. The training is available at both the pre-doctoral level. A PhD program may be completed in 5 years. At the postdoctoral level, qualified MD or PhD candidates complete 2 or more years of training. The program supports 14 post-doctoral trainees and 4 pre-doctoral trainees per year. A wide range of training opportunities are provided by a large interactive network of faculty supported by individual, collaborative and inter-institutional research grants. These opportunities include lung-related research in behavioral science, biomedical ethics, cellular and molecular biology, environmental science, epidemiology, health services, immunology and infection, airway biology, sleep biology and vascular biology. The close relationship between a primary mentor and co- mentors with the trainee is the core of the experience. This is supplemented by formal course work, core conferences, training in responsible research conduct, communication skills, career planning, and grant writing. Postdoctoral trainees in the clinical sciences can acquire a Masters or Doctoral. Fellows and mentors are reviewed by a committee that monitors the training and career development of fellows, and promotes mentoring skills. Doctoral students are reviewed by a thesis committee that provides both support and guidance. Since 1999, the program has trained 16 minority trainees reflecting its commitment to cultural diversity. This grant has supported 80 post-doctoral trainees: 88% took 3 or more years of research training; 89% entered full-time academic positions and 74% have obtained independent research funding including 32 K-awards and 40 F32 awards indicative of the program's success.

Public Health Relevance

Lung disease is a leading cause of death and disability in the United States. Despite an expanding understanding of the causes of lung disease, treatments that cure these disorders are lacking and most treatments are symptomatic or supportive. The goal of this program is to train highly qualified individuals in the research disciplines that are necessary to find better treatments for these disorders.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Institutional National Research Service Award (T32)
Project #
4T32HL007534-34
Application #
9064805
Study Section
NHLBI Institutional Training Mechanism Review Committee (NITM)
Program Officer
Colombini-Hatch, Sandra
Project Start
1982-07-01
Project End
2018-06-30
Budget Start
2016-07-01
Budget End
2017-06-30
Support Year
34
Fiscal Year
2016
Total Cost
Indirect Cost
Name
Johns Hopkins University
Department
Public Health & Prev Medicine
Type
Schools of Public Health
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21205
Qu, Yanyan; Olonisakin, Tolani; Bain, William et al. (2018) Thrombospondin-1 protects against pathogen-induced lung injury by limiting extracellular matrix proteolysis. JCI Insight 3:
Mallow, Christopher; Hayes, Margaret; Semaan, Roy et al. (2018) Minimally invasive palliative interventions in advanced lung cancer. Expert Rev Respir Med 12:605-614
Hager, David N; Tanykonda, Varshitha; Noorain, Zeba et al. (2018) Hospital mortality prediction for intermediate care patients: Assessing the generalizability of the Intermediate Care Unit Severity Score (IMCUSS). J Crit Care 46:94-98
Law, Anica C; Sahetya, Sarina; Walkey, Allan J et al. (2018) Low-dose corticosteroids and septic shock resolution: implications for randomized trial design? Intensive Care Med 44:1366-1367
Mills, Kelly A; Greene, M Claire; Dezube, Rebecca et al. (2018) Efficacy and tolerability of antidepressants in Parkinson's disease: A systematic review and network meta-analysis. Int J Geriatr Psychiatry 33:642-651
Suresh, Karthik; Servinsky, Laura; Jiang, Haiyang et al. (2018) Reactive oxygen species induced Ca2+ influx via TRPV4 and microvascular endothelial dysfunction in the SU5416/hypoxia model of pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol 314:L893-L907
Raju, Sarath; Keet, Corinne A; Paulin, Laura M et al. (2018) Rural Residence and Poverty are Independent Risk Factors for COPD in the United States. Am J Respir Crit Care Med :
Mallow, Christopher; Isakow, Warren (2018) Risk Factors for Loss of Lung Sliding in a Medical Intensive Care Population With Acute Respiratory Failure. J Bronchology Interv Pulmonol :
Bain, William; Lee, Janet S (2018) Ventilator Circuit Trash May Be a Research Treasure. Am J Respir Crit Care Med 197:979-980
Goodson, Carrie M; Chang, Yui; Arora, Rakesh C (2018) What type of delirium would you like: Hyperactive, hypoactive, or mixed? None, thanks. J Thorac Cardiovasc Surg 155:240-241

Showing the most recent 10 out of 112 publications